Clinical trial
Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents
NCT00387725 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00387725 |
|---|---|
| Title | Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents |
| Official title | A Randomized, Observer-blinded, Parallel-group, Active-control, Phase ½ Trial Of The Safety, Immunogenicity, And Tolerability Of 20 Mg, 60 Mg, And 200 Mg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological |
| Interventions | rLP2086 |
| Enrollment | 127 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Oct 13, 2006 |
| Last update posted | Nov 21, 2014 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: